Search research articles
Contact Us
Filters
Showing results (41-50 of 111) with videos related to
Page
of 12
Sort By:
Therapeutic Innovation & Regulatory Science
|
February 3, 2020
How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?
Michaela Tutone, Federico Villa, Antonio Addis, et al.
Archives of Disease in Childhood
|
September 16, 2018
Neonatal outcomes following new reimbursement limitations on palivizumab in Italy
Valeria Belleudi, Francesco Trotta, Luigi Pinnarelli, et al.
The Lancet. Infectious Diseases
|
January 26, 2013
Drotrecogin alfa (activated) in severe sepsis
Daniele Poole, Carlotta Rossi, Antonio Addis, et al.
European Journal of Clinical Pharmacology
|
January 9, 2017
Can systematic reviews contribute to regulatory decisions?
Corrado Barbui, Antonio Addis, Laura Amato, et al.
Journal of Clinical Epidemiology
|
May 20, 2018
Studies on drug switchability showed heterogeneity in methodological approaches: a scoping review
Valeria Belleudi, Francesco Trotta, Simona Vecchi, et al.
Medicine
|
June 9, 2021
Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study
Laura Angelici, Antonio Addis, Nera Agabiti, et al.
Recenti Progressi in Medicina
|
December 17, 2024
Michela Servadio, Valeria Belleudi, Marco Finocchietti, et al.
Intensive Care Medicine
|
February 28, 2007
Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey
Guido Bertolini, Carlotta Rossi, Abramo Anghileri, et al.
Journal of Nephrology
|
June 25, 2017
Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis
Laura Amato, Antonio Addis, Rosella Saulle, et al.
Recenti Progressi in Medicina
|
September 30, 2015
[Considerations on what we can (and what we should not) ask to registries]
Antonio Addis, Elena Berti, Rossana De Palma, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 111) with videos related to
Sort By:
Page
of 12
Therapeutic Innovation & Regulatory Science
|
February 3, 2020
How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?
Michaela Tutone, Federico Villa, Antonio Addis, et al.
Archives of Disease in Childhood
|
September 16, 2018
Neonatal outcomes following new reimbursement limitations on palivizumab in Italy
Valeria Belleudi, Francesco Trotta, Luigi Pinnarelli, et al.
The Lancet. Infectious Diseases
|
January 26, 2013
Drotrecogin alfa (activated) in severe sepsis
Daniele Poole, Carlotta Rossi, Antonio Addis, et al.
European Journal of Clinical Pharmacology
|
January 9, 2017
Can systematic reviews contribute to regulatory decisions?
Corrado Barbui, Antonio Addis, Laura Amato, et al.
Journal of Clinical Epidemiology
|
May 20, 2018
Studies on drug switchability showed heterogeneity in methodological approaches: a scoping review
Valeria Belleudi, Francesco Trotta, Simona Vecchi, et al.
Medicine
|
June 9, 2021
Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study
Laura Angelici, Antonio Addis, Nera Agabiti, et al.
Recenti Progressi in Medicina
|
December 17, 2024
Michela Servadio, Valeria Belleudi, Marco Finocchietti, et al.
Intensive Care Medicine
|
February 28, 2007
Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey
Guido Bertolini, Carlotta Rossi, Abramo Anghileri, et al.
Journal of Nephrology
|
June 25, 2017
Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis
Laura Amato, Antonio Addis, Rosella Saulle, et al.
Recenti Progressi in Medicina
|
September 30, 2015
[Considerations on what we can (and what we should not) ask to registries]
Antonio Addis, Elena Berti, Rossana De Palma, et al.
Page
of 12